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INTRODUCTION 
Cyclodextrins (CDs) have lipophilic inner cavity and hydrophilic outer surface (Fig.l) 
and thus are capable of interacting with a large variety of guest molecules to form non-
covalent inclusion complexes. Chemically they are cyclic oligosaccharides containing at 
least six D-(+) glucopyranose units linked by a-(l, 4) glucosidic bonds. CDs and their 
derivatives discussed here along with their abbreviations are given in Table 1. 
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Fig.l 
a -, P - and y -CDs (with 6, 7 and 8 glucose units, respectively) are three natural CDs 
1 
differing in their ring size and solubility (Table-2). CDs with less than six units are not 
known and probably cannot exist due to steric hindrances while the higher homologues 
with nine or more glucose units are difficult to purify. Endo et al. have, however, recently 
established an isolation and purification method for several large ring CDs and also 
obtained a relatively large amount of 8-CD (Cyclomaltonose) with nine glucose units.^'' 
The cavity size of a-CD is smallest and not suitable for complexation with many drugs 
while y-CD is quite expensive yet. 5-CD, in general, has weaker complex forming 
capability compared to conventional CDs due to large cavity size. With drugs like 
digitoxin and spiranolactone, 5-CD showed greater solubilizing effect than a-CD but was 
less than that of P- and y-CDs. P-CD has been widely used in early stages of 
pharmaceutical applications due to its ready availability and suitable cavity size for large 
variety of drugs. 
Chemically modified CD derivatives have been prepared with a view to improve the 
physicochemical properties and inclusion capabilities of parent CDs. Several amorphous, 
non-crystallizable CD derivatives with enhanced aqueous solubility, physical and 
microbiological stability, and reduced parenteral toxicity have been developed by 
chemical modification of parenteral CDs. '^ CDs and their derivatives have received 
considerable attention in the area of pharmaceutical sciences for the several years and an 
increased number of reviews have been dedicated to their industrial and pharmaceutical 
applications. ' 
FACTORS INFLUENCING INCLUSION COMPLEX FORMATION 
(TABLES 3, 4 & 5) 
Type of CD can influence the formation as well as the performance of inclusion complex 
of drugs with CDs.'^''^ For complexation, the size of the CD cavity should be suitable to 
accommodate a drug molecule of particular size.'^ '^ ^ Strong complexes may be formed 
when the CD and the drug carry opposite charges while poor complexation can be 
expected when they carry similar charges For many acidic drugs forming anions, the 
cationic (2-hydroxy-3-(trimethylammonio) propyl)-P-CD acted as an excellent 
solubilizer. The presence of charge may play a significant role in drug/CD complexation 
in case of ionizable drugs and hence a change in the solution pH can vary the binding 
constant of the complex. In general, ionic forms of drugs are weaker complex forming 
agents than their non ionic forms'^ '^ '^ but in case of mebendazole, the unionized form was 
found to be less included in HP-P-CD than its cationic form.^ '* 
Temperature changes can also affect drug/CD complexation. In most cases increasing the 
temperature decreased the magnitude of the apparent stability constant of drug/CD 
complex and the effect was reported to be a result of possible reduction of drug/CD 
attractive forces, such as van der waal and hydrophobic forces with the rise of 
temperature. " However, temperature changes may have negligible effect when the 
drug/CD interaction is predominantly entropy driven (i.e resulting from the liberation of 
water molecules hydrated around the charges of guest and host molecules through 
inclusion complexation).^^ 
SOME IMPORTANT CONSIDERATIONS FOR CD SELECTION IN DRUG 
FORMULATION 
Commercial Availability 
Of various CDs discussed in this article, the natural CDs and hydroxypropyl, 
hydroxylethyl, sulfobutyl and various methylated CD derivatives are available in bulk 
quantities while other CD derivatives are either synthesized in laboratory for the study or 
are available on laboratory scale. For research and investigational purposes, various CDs, 
natural and modified, including some sugar branched derivatives like Glucosyl and 
Maltosyl-P-CDs can be obtained from 'cyclodex' under the trade name 'trappsol'.^^ 
Regulatory Status 
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The global regulatory status of CDs has been discussed in the review by Thomson. 
Regulatory status of natural CDs is given in Table 6. Oral and i.v. solutions of 
itraconazole containing 3HP-P-CD (Sporanox by Janssen) were approved for marketing 
in USA and Belgium. 3HP-p-CD containing cisapride suppositories (Prepulsid by 
Janssen-Cilag) and diclofenac eye drops (by Ciba Vision) were also approved for 
marketing in Belgium and Switzerland, respectively.^' In the US, in August 1999, a type 
V DMF, containing information and safety data package of captisol (SBE7-P-CD with 
average degree of substitution of 6.5 from CyDex) was filed. An intramuscular Captisol-
® ® ® 
Enabled ziprasidone formulation (Geodon , Zeldox ) was the first captisol containing 
formulation to receive regulatory approval in Sweden (September, 2000), also approved 
in US and rest of Europe. Pfizer has also obtained European and US approval for a 
32 
captisol enabled IV formulation of voriconazole (Vfend ) 
Patent status 
Being known for several years, natural CDs would not ordinarily be considered as 
patentable subject matter, however, there are many unexpired patents claiming specific 
complexes of drugs with natural CDs, particularly with P-CD. The patent situation for 
CD derivatives varies for known derivatives and complexes. HP-P-CD and other 
hydroxyalkylated P-CD derivatives have been known for nearly twenty years and their 
basic patents have expired. However, potentially patentable drug complexes of HP-CDs 
and related derivatives have been developed. In the US, a patent claiming compositions 
containing an amorphous drug/CD complex and a method of producing such a complex 
with description of HP-P-CD as the most promising amorphous CD, was granted to 'US 
Department of Health and Human Services' on 23 February 1988 (US Patent No 
4,727,064). In Europe, the dominant patent position with respect to HP-P-CD belongs to 
Janssen Pharmaceutical Company of Belgium. The Janssen application relates to 
pharmaceutical compositions containing drugs, which are unstable or sparingly soluble in 
water, complexed with HP-P-CD or a related P-CD derivative. A European patent was 
issued to Janssen in 1990 with claims narrowed in the light of earlier work by Pitha. 
Between 1996 and 1999, Procter & Gamble filed and received at least 100 patents related 
to CD use in laundry and deodorizing applications.^" CyDex has exclusive rights to 
patents protecting the use and composition of matter of captisol. Exclusive rights to use 
captisol for antifungal and some specific ophthalmic applications have been granted by 
cydex to its client companies.^^ Pfizer undertook, in the mid 90's, to obtain patent 
protection for another chemically modified p-CD (sulfobutylether) for its own use?*^  
CD EFFECTS ON IMPORTANT DRUG PROPERTIES IN FORMULATION 
Effect on Drug Solubility and Dissolution 
CDs play a very important role in formulation of poorly water-soluble drugs by 
improving apparent drug solubility and/or dissolution through inclusion complexation or 
solid dispersion, by acting as hydrophilic carriers for drugs with inadequate molecular 
characteristics for complexation, or as tablet dissolution enhancers for drugs with high 
dose, with which use of drug/CD complex is difficult, e.g. paracetamol.^^ CD applications 
as solubilizing agents are summarized in Table 7. Of various commercially available 
CDs, methylated CDs with a relatively low molar substitution appear to be the most 
powerful solubilizers. Reduction of drug crystallinity on complexation or solid dispersion 
with CDs also contributes to the CD increased apparent drug solubility and dissolution 
rate.^ ''"'^  CDs, due to their ability to form in situ inclusion complexes in dissolution 
medium, can enhance drug dissolution even when there is no complexation in the solid 
state.^ ^ SBE-P-CD was shown to be an excellent solubilizer for several drugs and was 
more effective than P-CD but not as effective as DM-P-CD." CDs can also act as release 
enhancers, e.g. P-CD enhanced the release rate of poorly soluble naproxen and 
ketoprofen from inert acrylic resins and hydrophilic swellable (high viscosity hydroxy 
propyl methyl cellulose (HPMC)) tableted matrices. P-CD also enhanced the release of 
theophylline from HPMC matrix by increasing the apparent solubility and dissolution 
rateofthedrug.^^'^^ 
Effect on Drug Bioavailability 
The bioavailability of insoluble drugs can be enhanced by increasing the drug solubility, 
dissolution and/or drug permeability. The permeability of insoluble, hydrophobic drugs is 
increased by CDs by making the drug available at the surface of the biological barrier; 
e.g. skin, mucosa or the eye cornea, from where it partitions into the membrane without 
disrupting the lipid layers of the barrier. It is important, in such cases, to use CD just 
enough to solubilize the drug since excess CD may decrease the drug availability (Fig. 
2) 40-42 
Fig. 2: Mode of penetration enhancement by CDs 
At low RM-P-CD concentrations, when hydrocortisone was in suspension, increasing the 
CD concentration increased the drug flux. At higher CD concentrations, when the drug 
43 
was in solution, increasing the CD concentration decreased the flux. The drug 
permeability can further be enhanced by addition of polymers to aqueous CD solutions. 
Carboxymethyl cellulose (CMC) enhanced bioavailability of triclosan from toothpastes 
containing P-CD by forming drug/CD/CMC complex with improved substantivity.""' CDs 
increased the bioavailability of lipophilic itraconazole from both an oral solution as well 
45 as intravenous formulation by improving the drug solubility and absorption. 
In the case of drugs which are water soluble, CDs increase drug permeability by direct 
action on mucosal membranes and enhance drug absorption and/or bioavailability.^ '*'^  
Solubilization of specific membrane lipids of human erythrocytes through inclusion 
complexation with CDs and their ability to cause perturbation of membrane integrity, has 
been suggested to contribute to CD induced promotion of drug absorption. It has been 
reported that CDs, due to their ability to remove cholesterol, may increase membrane 
fluidity and induce membrane invagination through a loss of bending resistance and 
cause cell lysis. On the other hand, removal of phospholipids, especially 
phosphatidylcholine and sphingomyelin from the outer half of membrane bilayer by CDs 
causes bilayer imbalance, the removal may also contribute in part to the formation of 
stomatocytes through an inward bending of membranes. CD induced lysis of artificial 
membranes composed of lecithin and cholesterol by a similar solubilization process. 
Detergents first incorporate themselves into membranes, then extract the membrane 
components into micelles and cause membrane solubilization/lysis. However, unlike 
detergents, CDs were reported to solubilize membrane components without entering into 
the membrane and hence the perturbing effects of CDs can be mild and reversible. In 
presence of CDs, the new lipid containing compartment in the aqueous phase with 
extracted components from the erythrocyte surface equilibrated freely with the cell 
surface by a reversible process. Compared to other absorption promoting agents and 
preservatives commonly used in nasal formulations, CDs exert a rather mild and 
reversible effect on the ciliary beat frequency of both chicken embryo trachea and human 
nasal adenoid tissue in vitro in a concentration dependent manner." DM-P-CD caused 
enhancement of enoxaparin nasal absorption by solubilizing membrane components and 
opening tight junctions but the effect was reversible after 6 hrs.*^ Watanabe et al. reported 
that rectal membrane recovers its barrier function probably about 24 h after the 
administration of DM-P-CD (at least 30 mg).^Even at high doses the effects of HP-P-CD 
on kidneys were reversible and similar to those of osmotic agents currently used in 
parenteral formulations.''" Labile drug stabilization by CDs"**'^ ^ and their ability to 
ameliorate drug irritation, and thus improve drug contact time at the absorption site in 
nasal, ocular, rectal and transdermal delivery are some other important factors that 
contribute to the CD improved bioavailability. a-CD improved the rectal bioavailability 
of morphine by inhibiting the drug upward movement from areas impacted by first pass 
metabolism.^ 
Effect on Drug Safety 
CDs have been used to ameliorate the irritation caused by drugs. ^ The drug efficacy and 
potency is increased (i.e. reduction of the dose required for optimum therapeutic activity), 
caused by CD increased drug solubility, may reduce drug toxicity by making the drug 
effective at lower concentrations. The antiviral activity of ganciclovir was ehanced by P-
CD on human cytomegalovirus clinical strains and the resultant increase in the drug 
potency reduced the drug toxicity.^ '* The toxicities associated with crystallization of 
poorly water-soluble drugs in parenteral formulations can often be reduced by formation 
of soluble drug/CD complexes. Formulation of phenytoin with HP-p-CD showed 
considerably reduced tissue irritation compared to a commercial injection of the drug in a 
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BALB/c mouse model.^ ^ Further CD entrapment of drugs at molecular level prevents 
their direct contact with biological membranes and thus reduces their side effects (by 
decreasing drug entry into the cells of non-targeted tissues) and local irritation with no 
drastic loss of therapeutic benefits.'^ Inclusion complexation with HP-P-CD reduced the 
side effects of 2-ethylhexyl-p-dimethyl aminobenzoate (a UV filter) by limiting the 
interaction of the UV filter with skin.^ ^ In a study with patients, piroxicam/p-CD 
inclusion complex showed better tolerance with lower incidence and severity of 
gastrointestinal side effects compared to the free drug.^ ^ HP-P-CD alleviated the intrinsic 
irritancy effect observed on i.v administration of CKD-732 hemioxalate against blood 
CO 
vessels. Inclusion complexation with CDs also reduces ocular drug irritation by limiting 
the free drug concentration on the pre-corneal area to a non-irritating level.^ ^ 
Effect on Drug Stability 
CDs have been used to improve the stability of a number of drugs against dehydration, 
hydrolysis, oxidation and photodecomposition and thus increase the shelf life of drugs. 
Table 8. summarizes CD effects on drug stability. It has been reported that CD induced 
enhancement of drug stability may be due to inhibition of drug interaction with vehicles 
and/or inhibition of drug bioconversion at the absorption site.^ By providing molecular 
shield, CD complexation encapsulates labile drug molecules at molecular level and thus 
insulates them against various degradation processes. SBE-P-CD showed greater stability 
enhancement for many chemically unstable drugs than other CDs." 
The stabilizing effect of CDs depends on the nature and effect of the included functional 
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group on the drug stability and the nature of the vehicle. Both the catalyzing effect of 
nitro group as well as the stabilizing effect of halogen and cyanogen groups on 
photodegradation of 1, 4 dihydropyrimidine derivatives were reduced by complexation 
with CDs.^ *^  HP-P-CD significantly reduces the photodegradation of 2-ethylhexyl-p-
dimethylaminobenzoate in solution than in emulsion vehicle.^^ CDs improved the 
photostability of trimeprazine (when the solution pH is reduced) and promethazine. 
CDs can also enhance the solid state stability and shelf life of drugs.^ "^^ '* CDs were 
reported to enhance the physical stability of viral vectors for gene therapy and the 
formulations containing sucrose and CDs were stable for 2 years when stored at 20 C 
since the hydrolysis of drugs encapsulated in CDs is slower than that of free drugs. 
The stability of drug/CD complex i.e. the magnitude of the complex stability constant 
plays significant role in determining the extent of protection.'^ '^^ '^^ ^ Very low 
concentrations of HP-^-CD (1% or lower), due to formation of a more physically 
unstable complex, did not protect taxol as effectively as higher CD concentrations. 
Under specific conditions, CD complexation may accelerate drug degradation depending 
on the type of the CD. CDs catalyzed deacetylation and degradation of spiranolactone, 
the effect was qualitatively correlated with the ionization state of hydroxyl groups on 
CDs that were lower in SBE-CDs.^^ Structural changes in drug molecules on CD 
complexation can also accelerate drug degradation.''^ P-CD did not improve the 
photostability of oflaxacin as there was only a partial inclusion of the methyl piperazinyl 
moiety in the CD.^' 
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GD APPLICATIONS IN DRUG DELIVERY 
Oral Drug Delivery 
CDs are used in oral drug delivery for the improvement of drug bioavailability due to 
increased drug solubility, improvement of rate and extent of dissolution, and/or stability 
of the drug at the absorption site, reduction of drug induced irritation, and taste masking 
etc Table 9. CD complexation has been found to decrease local drug irritation and to 
modify the time of drug release during gastrointestinal transit.'^'''° An itraconazole oral 
preparation containing 40% (w/v) of HP-P-CD (with reduced drug irritation) has been 
commercialized in US and Europe?^ CDs enhance the mucosal drug permeability mainly 
by increasing the free drug availability at the absorptive surface.^ '^^ ^ CD complexation 
can provide better and uniform absorption of poorly soluble drugs with poor and erratic 
absorption '^* and also can enhance the drug activity on oral administration.^ '^^ ^ CD 
complexation increased the anthelmentic activity of albendazole and provided a high 
plasma concentration of the active metabolite.'^ The absorption of poorly water-soluble 
drugs has been increased by CD complexation, delivered via buccal or sublingual 
mucosa.'^ '*^ Complexation of miconazole, econazole and clotrimazole with HP-P-CD and 
genuine CDs increased the toxicity of these drugs on a human buccal cell culture model 
(TRi46) by causing super saturation by the drug.^ ^ 
Captisol or (SBE)7M-P-CD, a solubilizer with osmotic property has been used to design 
osmotic pump tablets of chlorpromazine and prednisolone. '^''^ ^ Complexation can also 
mask the undesirable taste of drugs. Complexation of oxyphenonium bromide with CDs 
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suppressed its bitter taste. With the assumption that only the free drug molecule exhibits 
bitter taste the extent of the suppression was reported to be dependent on the availability 
of free drug, regardless of the kind and concentration of CD.^ ^ 
The relative safety, efficacy in terms of complexation, cost and acceptance in 
pharmacopoeias are some important factors to be considered in selecting a CD for drug 
complexation. HP-P-CDs were shown to have a better oral safety profile than P-CD and 
other parent CDs, but only limited data is available on the oral safety of the methylated 
CDs. However, for oral administration all CDs can be considered practically nontoxic 
due to lack of CD absorption through GIT and hence, the relative safety profile of CDs is 
a concern of drug doses used in drug/CD complexes and the LD50 of CD.'^ ^ P-CD is the 
most cost-effective of all the CDs whereas HP-P- and SBE-P-CDs are more expensive. 
Monograph of P-CD is already incorporated in various pharmacopoeias.' P-CD can, 
therefore, be considered optimum for oral use when it is effective for drug complexation 
and modified CDs like HP-, SBE-P- and DM-P-CDs may be used when they are more 
effective and when their peculiar property is required in formulation, eg. SBE-P-CD has 
been used in the preparation of osmotic pump tablets due to its osmotic property.^ "*'^ ^ 
Parenteral Drug Delivery 
CD derivatives such as amorphous HP-P- and SBE-p-CDs have been widely investigated 
for parenteral use on account of their high aqueous solubility and minimal toxicity. HP-p-
CD with much higher aqueous solubility allows parenteral administration of various 
drugs with no significant toxicity problems and hence is more preferred in parenteral 
formulations. An itraconazole parenteral injection containing HP-P-CD (40% w/v) has 
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been commercialized in USA and Europe?^ The solubilizing potentials of both the SBE-
P- & HP-P-CDs for the drugs, melphalan and carmustine, were compared and were found 
to be qualitatively similar but the intrinsic reactivity was significantly less with SBE-P-
Applications of CDs in parenteral delivery are solubilization of drugs, reduction of drug 
irritation at the site of administration and stabilization of drugs unstable in aqueous 
environment etc. Singla et al discussed the use of CDs for the enhancement of the 
solubility and stability of paclitaxel in formulations; and mentioned that the approach 
needs further research to overcome the serious limitations of CD based formulations.^'An 
i.m. dosage form of ziprasidone mesylate with targeted concentration of 20-40 mg/ ml 
was developed by inclusion complexation of the drug with SBE-P-CD.^^ Formation of a 
stable, water-soluble dexamethasone complex with sugar branched P-CDs suggested the 
potential of these CDs as excellent carriers in steroidal injectable formulations.^^ 
Aqueous phenytoin parenteral formulations containing HP-P-CD exhibited reduced tissue 
irritation and precipitating tendency as their pH values were significantly closer to the 
physiological value (7.4).^* SBE-P-CD has been found to be useful in the preparation of 
parenteral solutions of poorly water-soluble drugs with positive charge, such as DY-
9760e.^' 
Effects of CDs on drug pharmacokinetics were discussed by Stella and Rajewski.^ ^ 
Miconazole formulations solubilized by HP-P- and SBE-7-p-CDs showed no significant 
effect on the drug pharmacokinetics in sheep compared to the drug micellar solution 
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solubilized by cretnophor EL (polyoxyl-35 caster oil). Synergistic effect of CDs with 
on 
acids, like lactic acid, was used to solubilize miconazole for safe parenteral delivery. In 
some cases complexation may affect drug pharmacokinetics, for eg. complexation with 
sugar branched P-CDs altered the disposition of dexamethasone in mice. The binding 
values of diflunisal in plasma solutions containing HP-P-CD were found to be lower than 
the theoretical due to competitive displacement of the drug from the CD by plasma 
cholesterol.^^ In rabbits, co-administration of M-P-CD with doxorubicin resulted in 
reduced distribution half-life and modified renal and hepatic distribution profiles of the 
drug, but the main pharmacokinetic parameters of the CD were unaltered.^' 
A water-soluble CD derivative with low hemolytic activity has been synthesized by 
acetylation of free hydroxyl groups of DM-P-CD. The inclusion capacity of the obtained 
heptakis (2,6 di-0-methyl-3-0-acetyl)-p-CD (DMA-P-CD) was found same as that of 
DM-P-CD but the new derivative showed less irritation in rabbits with no hemolysis even 
at 0.1 M concentration. 
Ocular Deliver)' 
Applications of CDs in aqueous eye drop preparations include solubilization and 
chemical stabilization of drugs, reduction of ocular drug irritation and enhancement of 
ocular drug permeability etc. Vehicles used in ophthalmic preparations should be non-
irritating to the ocular surface to prevent fast washout of the instilled drug by reflex 
tearing and blinking. Hydrophilic CDs, especially 2HP-P- and SBE-p-CDs have been 
shown to be non-toxic to the eye and are well tolerated in aqueous eye drop formulations, 
e.g. ocular absorption and shelf life of pilocarpine in eye drop solutions increased by 
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complexation with SBE-P-CD; and ocular irritation of a lipophilic pilocarpine prodrug 
were reduced by SBE-P- and HP-P-CDs.' Loftsson and Stefansson have reviewed the 
effects of CDs and aqueous CD containing formulations on the ocular drug 
bioavailability and have also discussed the effect of polymers on CD induced drug 
solubilization and permeability enhancement Table 10.'*''^ ^ The cytotoxicity of CDs on 
human corneal cell line was found to be in the order, a-CD > DM-P-CD > SBE-P-CD = 
HP-P-CD > y-CD. It has been suggested that ocular toxicity with SBE-P-CD (lOOmM) 
after 1 hr of its exposure could be possibly due to its high osmotic pressure. However, the 
toxicity with negatively charged SBE-P-CD was greater compared to the control, a 
neutral hypertonic mannitol solution.^ ^ CDs also enhance drug permeability by making 
the drug available at the ocular surface. HP-P-CD enhanced the ocular permeability of 
dexamethasone acetate and also inhibited the conversion of acetate salt to less permeable 
dexamethasone.^ '* Since only the free drug can permeate biological membranes, 
ophthalmic delivery of drugs can be limited by the dissociation of drug/CD complexes in 
the pre-corneal area due to the limited dilution in this area. The dissociation of drug/CD 
complexes depends more on the binding of drugs to pre-corneal proteins, absorption by 
corneal tissue and displacement of drugs from CD complexes by pre-corneal fluid 
components.'^ The ability of CDs to decrease membrane lipophilicity by interacting with 
the lipophilic compounds of epithelium was indicated by the reduction in the 
bioavailability of highly lipophilic pilocarpine prodrugs by the addition of CDs.^ ^ 
Complexation with HP-P-CD significantly decreased hydrocortisone transport from 
aqueous to organic phase, the effect was dependent on the drug partition coefficient and 
the relative magnitude of the stability constant of the inclusion complex. The polymer 
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interactions with the drug, hydrocortisone and its complex in each system were reported 
to be responsible for the observed solubility and different release behaviors of 
hydrocortisone and its inclusion complex from high molecular weight cellulose and PVA 
polymeric films for ocular delivery.^^ Formulation with HP-p-CD, with and without 
HPMC, improved the bioavailability and maximal mydriatic response of tropicamide by 
enhancing the drug ocular permeability, but reduced the ocular drug irritation, probably 
by maintaining the pH in physiologic range. HP-fi-CD also enhanced the permeability 
and miotic response of pilocarpine nitrate without damaging the rabbit corneal tissue.^'' 
Nasal Drug Delivery 
CDs are effective excipients in nasal drug delivery also. CDs can improve nasal drug 
absorption either by increasing aqueous drug solubility and/or by enhancing nasal drug 
permeability. The safety and non-toxicity of CDs in nasal drug formulations have been 
demonstrated by the clinical data with CDs showing no adverse effects. Merkus et al. 
demonstrated that CDs are safe to be used to improve nasal bioavailability of drugs, 
especially peptides. DM-P-CD was reported to improve the nasal bioavailability of 
estradiol in rats and rabbits. Nasal absorption of melatonin, a drug with high first pass 
metabolism was rapid and efficient when administered with P-CD and the peak levels 
were about 50-times higher than those observed after oral administration.'^ Midazolam is 
absorbed rapidly when administered as an aqueous nasal spray (pH 4.3) containing SBE-
P-CD (14% w/v), HPMC (0.1% w/v) and other additives.^' 
CDs can also be used to reduce the nasal toxicity of other enhancers without affecting 
their absorption enhancing property. P-CD or DM-P-CD reduced the serious nasal 
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toxicity of sodium deoxycholate by inhibiting the leucine aminopeptidase activity in 
nasal mucosa without affecting the absorption enhancing property of the bile salt for 
insulin.'°° Salbutamol release from the powder inhaler formulations containing y-CD and 
DM-P-CD was faster than from control with lactose and, at the amount studied, y-CD was 
safer than DM-P-CD.'°' Midazolam nasal formulation in aqueous SBE-P-CD solution 
approached an i.v. form of the drug in speed of absorption, serum concentration and 
sedation effect, with no serious side effects.'"^ 
Rectal Drug Delivery 
Applications of CDs in rectal delivery include enhancing drug absorption from 
suppository base either by enhancing drug release from the base or by increasing drug 
mucosal permeability, increasing drug stability in the base or at the absorption site, 
providing sustained drug release, and alleviating drug induced irritation. '^ "^  
Drug release from suppository base is important in rectal absorption due to the high 
viscosity of rectal fluids. The effect of CDs on rectal drug absorption is influenced by 
partition coefficient of the drug and its CD complex, magnitude of the stability constant 
of complex and nature of the suppository base (oleaginous or hydrophilic). Hydrophilic 
CDs (especially methylated and hydroxylpropyl CDs) enhance the absorption of 
lipophilic drugs by improving the drug release from oleaginous vehicles and/or by 
increasing the drug dissolution rate in rectal fluids. Formation of hydrophilic CD 
complexes was found to inhibit the reverse diffusion of drugs into oleaginous vehicles by 
reducing the drug/ vehicle interaction. Rectal absorptions of flurbiprofen and 
biphenylacetic acid were found to be enhanced by DM-^-CD and HP-P-CD, respectively. 
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CDs may not affect drug release if the drug/CD complex dissociates in the vehicle itself, 
e.g. though the dissolution rate of ethyl 4-biphenylylacetate (EBA) was highest from 
DM-P-CD complex, only HP-P-CD complex enhanced EBA release from the oleaginous 
suppository base due to lower dissociation of HP-P-CD complex in the vehicle. CD 
complex, once released from the base, mostly releases the free drug for absorption. The 
competing sites for the free drug released at the absorption site are CD cavity, 
suppository base and the rectal mucosa. The extent of drug diffusion into these sites 
depends on drug's partition coefficient, magnitude of the stability constant of drug/CD 
complex and the relative lipophilicity of the competing sites. In case of lipophilic drugs 
with high partition coefficient, there might be some back diffusion of the released free 
drug into the lipophilic base. Since a part of drug may get absorbed as CD complex, the 
partition coefficient of the complex also becomes important, e.g. rectal absorption of a 
part of EBA as HP-P-CD complex. In the presence of hydroxyl propyl methyl cellulose 
(HPMC), P-CD markedly reduced the bioavailability of acetaminophen from both 
aqueous solution and hydrogels by forming a complex with lower partition coefficient or 
higher hydrophilicity ^ 
CDs can enhance the rectal absorption of inabsorbable, hydrophilic drugs such as 
antibiotics, peptides and proteins by their direct action on the rectal epithelial cells. a-CD 
enhanced the rectal absorption of morphine and human chorionic gonadotropin by 
increasing their mucosal permeability and reducing their degradation.'°^''°'* CDs enhance 
rectal drug stability either by inhibiting the drug/vehicle interaction (by making the drug 
insoluble in oleaginous base) or by inhibiting the drug bioconversion in the rectum. a-CD 
improved the rectal bioavailability of morphine by inhibiting the upward movement of 
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the drug from areas impacted by first pass metabolism. 
Controlled Drug Delivery 
CDs, due to their ability either to complex with the drugs or to act as functional carrier 
materials in pharmaceutical formulations, can be used as potential candidates for efficient 
and precise delivery of required amounts of drugs to targeted site for a necessary period 
of time. p-CD derivatives are classified as hydrophilic, hydrophobic and ionisable 
derivatives. The hydrophilic derivatives improve the aqueous solubility and dissolution 
rate of poorly water soluble drugs while the hydrophobic derivatives retard the 
dissolution rate of water soluble drugs from vehicles. Hence hydrophilic and hydrophobic 
CD derivatives are used in immediate and prolonged release type formulations, 
respectively. The ionisable CD derivatives, on the other hand improve inclusion capacity, 
modify drug dissolution rate and alleviate drug irritation, e.g. use of CME-P-CD to obtain 
delayed release type formulations. Highly hydrophilic derivatives, such as 2HP-P-, G2 -
P- and SBE-p-CDs were used in immediate release formulations that dissolve readily in 
the GIT and enhance the oral bioavailability of poorly water soluble drugs. CDs, both 
natural and chemically modified, are used in the design of immediate, delayed release 
and targeted drug delivery systems etc. Table 11. The pH-dependent solubility of CME-
P-CD (i.e. limited solubility under the acidic conditions of stomach with the complex 
solubility increasing with pH), which provides selective dissolution of drug/CD complex, 
makes it useful in the design of enteric formulations. When molsidomine tablets 
containing CME-P-CD were studied in gastric acidity controlled dogs, the absorption of 
the drug was significantly retarded under high gastric acidity compared to low gastric 
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acidity conditions.'°^''°^ Hydrophobic CDs, such as alkylated and acylated derivatives, 
are useful as slow-release carriers in prolonged release formulations of water-soluble 
drugs. Applications of various CD derivatives in formulation of modified-release 
preparations are summarized in Table 12. '°^-'°^ Among the alkylated CDs, DE-P- and 
TE-p-CDs were the first used slow release carriers and their hydrophobic complexes with 
diltiazem'^^ and isosorbide dinitrate'°^ provided slow drug release on oral administration 
in dogs. Peracylated CDs, particularly those with medium alkyl chain lengths (C4-C6) 
were found to be useful as hydrophobic carriers and have broad applicability in various 
routes of administration. Combination of short and long chain peracylated P-CDs in an 
appropriate molar ratio was suggested to be useful to provide, effectively controlled 
release rate of water-soluble drugs, e.g. markedly retarded release rate of molsidomine on 
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complexation with peracylated P-CDs. TB-P-CD was suggested to be a useful carrier 
for oral administration of water-soluble drugs, especially those that are metabolized in the 
GIT. In beagle dogs, oral administration of molsidomine as TB-p-CD complexes resulted 
in suppressed peak plasma level of the drug while maintaining sufficient drug levels for 
long periods. The increased hydrophobicity and mucoadhesive properties on 
complexation were reported to be responsible for the observed sustained effect with TB-
P-CD. Nanospheres of amphiphilic CDs such as DH-P-CD were also reported to have 
bioadhesive effects on gastrointestinal mucosa.'°^ 
CDs are also used along with other carrier materials to optimize drug release rate. 
Improved nifedipine bioavailability with reduced first pass metabolism was observed 
from a modified oral dosage form containing a fast release portion of the drug with HP-
P-CD and HCO-60, a non ionic surfactant (i.e amorphous drug form obtained by spray 
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drying with the CD and surfactant) and a slow release portion with hydroxy propyl 
celluloses (HPCs) of different viscosity grades."^ Quaglia et.al reported that CDs are 
useful to modulate drug delivery from swellable systems; e.g. P-CD significantly affected 
the delivery of nicardipine from swellable cross linked polyethylene glycol matrix by 
decreasing effective drug diffusivity through the matrix." SBE-P-CD has been used in 
the design of sustained release matrix tablets of poorly water soluble drugs. Directly 
compressed tablets containing prednisolone with SBE-P-CD and polymer physical 
mixture showed enhanced drug release than the control (with lactose instead of the CD) 
due to formation of an in situ drug/CD complex in the gel layer."^ HP-p-CD, due to its 
dissolution enhancing effect, was found to be more effective than P-CD in the 
development of controlled release nicardipine formulations."^ Combination of drug 
complexes with hydrophilic and hydrophobic CDs in appropriate ratios can be a 
promising drug delivery system for prolonged therapeutic effect and balanced 
bioavailability. In rabbits, a sustained release nicardipine formulation, developed by 
mixing the drug complexes with HP-P-CD (fast release fraction) and with hydrophobic 
TA-P-CD (sustained releasing portion) in appropriate ratios, showed markedly retarded 
drug release with prolonged maintenance of plasma levels."'' A sustained release two-
layered nifedipine tablet formulation was developed by using the drug complexes with P-
and HP-P-CDs."^ Use of CDs with a hydroxyl apatite matrix was indicated to control the 
release of chemotherapeutic agents containing toxic metals, such as Rhodium II citrate 
and butyrate, and to provide localized anti-tumor chemotherapy with minimal side 
effects."^ 
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Colon Specific Drug Delivery 
CDs are barely hydrolysed and only slightly absorbed in stomach and small intestine but 
are absorbed in large intestine after fermentation into small saccharides by colonic 
microbial flora. The peculiar hydrolyzing property of CDs makes them useful for colon 
drug targeting. Biphenyi acetic acid (BPAA) prodrugs for colon specific delivery were 
developed by conjugation of the drug onto one of the primary hydroxyl groups of a-, P-, 
and y-CDs through an ester or amide linkage. In case of ester prodrugs, the maltose and 
triose conjugates released the free drug after initial hydrolysis of the susceptible ester 
linkage, but in case of amide prodrugs, the conjugates remained as such providing 
delayed release due to the resistance of the amide bond to hydrolysis. CD based prodrug 
approach was used for colon specific and delayed drug delivery, e.g. when tested in rats 
with carageenan induced inflammation, the absorption of BPAA from y-CD prodrugs was 
found to be from cecum and colon in contrast to that from the highly soluble J3-CD 
complex, which was mainly from the small intestine."^ When studied in rats, it was 
found that both sugar degrading and ester hydrolyzing enzymes are necessary for colon 
specific release of butyric acid from its [3-CD ester conjugates."^ Drug conjugation with 
a-CD resulted in a delayed release type prodrug formulation for colon specific delivery 
that alleviates the side effects of drugs while maintaining their therapeutic effect, e.g. site 
specific degradation of prednisolone/a-CD conjugates in the large intestine alleviated the 
side effects of the drug while maintaining its anti-inflammatory action."^ 
Complexation of triamcinolone acetonide (TA) with P-CD improved the sphericity of 
micro-crystalline cellulose (MCC)-p-CD-TA spherical pellets prepared by extrusion and 
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spheronization for colon targeting. Triamcinolone acetonide complexation with the CD 
also facilitated the application of coating resistant to gastric and small intestinal media 
and maintained the pellet integrity in dissolution medium with no premature bursting of 
coatings on granule swelling. 
Peptide and Protein Delivery 
Various problems associated in practical use of therapeutic peptides and proteins are their 
chemical and enzymatic instability, poor absorption through biological membranes, rapid 
plasma clearance, peculiar dose response curves, and immunogenicity. CDs, due to their 
bioadaptability in pharmaceutical use and ability to interact with cellular membranes, can 
act as potential carriers for the delivery of proteins, peptides and oligonucleotide drugs.'^' 
The existence of efflux pumps may serve as an additional barrier for nonspecific uptake 
of peptides and thus can cause low peptide bioavailability. P-glycoprotein (P-gp) is an 
efflux transporter present in the apical region of epithelial cells in the brain, kidney, liver 
and GI tract. P-gp opposes the trans-cellular drug movement in the epithelial cells and 
several peptide drugs, especially hydrophobic peptides like cyclosporin A,''^ D, N-acetyl-
leucyl-leucylnorleucinal,'^^ valinomycin,'^'' gramicidin,'^^and ditekiren '^ ^ etc are 
reported to be substrates for this efflux transporter. Therapeutic use of peptides across the 
blood brain barrier (BBB) is greatly hindered by their very low penetration and it was 
reported that P-gp substrates, such as synthetic hydrophobic peptides, can stimulate the 
transport of drugs across BBB. An apically polarized verapamil sensitive efflux system 
for small hydrophobic peptides has been found in the BBB of rats. It was also reported 
that P-gp mediated transport of peptides might play an important role in greatly reducing 
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their delivery to the central nervous system in vivo. Hence, whenever unexplainable 
poor peptide absorption is seen, the role of efflux pumps should be examined.'^^ 
It was found that CDs can inhibit or impair the efflux function of P-gp and multidrug 
resistance associated proteins (MRP2). Out of various P-CD derivatives studied, DM-p-
CD has been found to be most effective and impairs significantly the efflux function of P-
gp and MRP2 in Caco cell monolayers (Caco2, Caco-2R) without changing the cell 
viability and membrane integrity. The inclusion ability of DM-P-CD, causing the release 
of the transporters (P-gp, MRP2) from the apical membranes of monolayers, was reported 
to be the probable reason for the observed impaired efflux function of the transporters in 
the presence of the CD. Not only the extraction of cholesterol but also that of 
phospholipids from the monolayers was found to be required for the CD induced 
inhibitory effect on the efflux function.'^ ^ In addition to the solubilizing effect of DM- P-
CD, its ability to inhibit P-gp efflux of tacrolimus from intestinal epithelial cells 
contributed to the CD induced enhancement of the drug oral bioavailability. Pretreatment 
of the apical membranes of the Caco cell monolayers with DM-P-CD decreased the 
efflux of tacrolimus and rhodamine with no associated cytotoxicity. DM-p-CD has also 
been found to decrease the level of P-gp in the apical membranes of the monolayers 
probably by allowing its release from the apical membranes into the transport buffer.'^ ° 
CDs were found to be useful in the absorption enhancement of calcitonin, glucagon, 
insulin and recombinant human granulocyte colony stimulating factor. DM-P-CD (5%) 
enhanced the intranasal calcitonin absorption in rats and rabbits and in rabbits the 
intranasal absorption was comparable to intravenous or subcutaneous calcitonin 
absorption. In rabbits, a nasal spray of liquid and powder formulations of glucagons 
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containing DM-P-CD provided improved bioavailability (> 80%) of glucagons compared 
to their subcutaneous administration. The absolute bioavailability of insulin in rats was 
also increased to about 100% on nasal administration with DM-P-CD (3 to 5%).^ * P-CD 
or DM-P-CD reduced the serious nasal toxicity of sodium deoxycholate (a bile salt) by 
inhibiting the leucine aminopeptidase activity in the nasal mucosa without affecting the 
absorption enhancing property of the bile salt for insulin.'°° The various established 
mechanisms for CD improved nasal absorption of peptides are interaction with 
membrane lipids and proteins in the nasal epithelium that reduces the membrane barrier 
function, inhibition of proteolytic enzyme activities in the nasal mucosa and finally 
inhibition of protein or peptide aggregation by direct action upon these molecules. Since 
the absorption enhancing effects of CDs are reversible, as enhancers they are less toxic 
than other widely used enhancers, e.g. the effect of CDs on the nasal cilliary beat 
frequency were observed to be mild, reversible and less toxic. However substantial 
interspecies differences were observed in the absorption enhancement of peptides from 
CD solutions. DM-P-CD, the only effective nasal absorption enhancer out of several 
CDs studied, largely improved the nasal absorption of insulin and ACTH from solutions 
in rats (bioavailability about 70-100%) but in rabbits and healthy human volunteers, the 
same CD/insulin solution was found to be ineffective. Improved bioavailability of insulin 
(uptol3%) was observed on nasal administration of powder formulations containing DM-
P-CD compared to the control containing lactose instead of the CD.'^' 
CDs can enhance physical and chemical stability of protein and peptide drugs, and the 
maximum enhancing effects were reported at low CD concentrations. The proteolytic 
degradation of basic fibroblast growth factor was decreased by water-soluble P-CD 
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sulfate.' P-CD improved insulin loading of alginate microspheres prepared by an 
emulsion-based process. The process was suggested to be useful in the development of an 
oral insulin drug delivery system as the absorption of insulin from optimized 
microspheres was found to take place from GI region.'^^ 
Gene and Oligonucleotide Delivery 
The need for the development of non-viral vectors for gene delivery arises from the 
toxicity and immunogenicity associated with viral vectors. Besides the plasmid or virus 
based vector systems, 'naked' nucleotide derivatives have also been investigated for 
possible use as therapeutic agents through several routes of administration. Gene delivery 
technologists are now testing CDs in the hope of finding an optimal carrier for the 
delivery of therapeutic nucleic acids. However, the limitations of CDs, such as CD 
associated toxicity (e.g. DM-P-CD) have to be considered before their clinical use.'"CDs 
can solve many of the problems associated with in vivo delivery of oligonucleotides such 
as, their limited ability to extravasate from blood stream and traverse cellular membranes, 
high degree of susceptibility to endonucleases with potential toxicity of their breakdown 
products, polyanionic nature leading to non-specific interactions with extra and 
intracellular cationic molecules, and potential immunogenicity. CDs can improve cellular 
uptake of oligonucleotides and also delay their degradation by increasing their stability 
against endonucleases. Oligonucleotides-adamantane conjugates associated with HP-P-
CD provided significantly increased cellular uptake of oligonucleotides. Substitution of at 
least a single nucleotide of oligonucleotides with CDs improved the cellular uptake 
and/or stability of oligonucleotides. On conjugation with CDs, oligonucleotides may be 
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delivered to colon, an advantageous absorption site to achieve acceptable therapeutic 
levels of oligonucleotides. CDs can also modulate undesirable side effects of 
oligonucleotide treatment such as, immune stimulation and reduction of platelet 
counts.'^ ^-'^ ^ 
Neutral, amphiphilic as well as cationic CDs have been used for synthesis of novel gene 
delivery vectors. Neutral CDs like (3-, DM-^- and HP-P-CDs have been reported to 
increase DNA cellular uptake by increasing its permeability. The increased DNA 
permeability was reported to be a result of interaction of the CDs with membrane 
components such as cholesterol but not due to their complexing ability for DNA. Cationic 
polyamino CDs, due to their polycationic-polyanionic interaction with mononucleotides, 
neutralized the multiple charges on DNA and thus made DNA to compact into a particle 
of suitable size for cellular internalization. Amphiphilic CDs, due to their vesicle forming 
potential, offer an additional possibility for polar nucleotides to complex into aqueous 
vesicle core while allowing hydrophobic agents to complex into individual cavities or 
interior of the bilayer with multiple lipophilic hydrocarbon. Polyplexes (polycation 
polymer/DNA composite structures) of linear, cationic, P-CD containing polymers 
(PCDPs) were found to be suitable for DNA delivery due to their increased transfection 
efficiency and stability against enzymatic degradation with low in vitro and in vivo 
toxicity chains.'^ ^"'^ ^ The ability of CDs to complex hydrophobic adamantane was 
exploited for steric stabilization of pCDPs with hydrophilic polymers like poly(ethylene 
glycol). Steric stabilization of pCDPs prevents their self-aggregation but facilitates their 
targeted delivery by preventing their undesired interactions with non-self-entities.'^'' 
CDs have also been found to enhance plasmid or viral-vector based delivery of genes. 
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Positively charged quarternary ammmonim and tertiary amino (3-CDs significantly 
enhanced the transfection efficiency of negatively charged adenoviral vector based gene 
formulations. It was reported that the transfection enhancement by the cationic (3-CDs 
could be due to increased viral internalization caused by increased viral binding to cell 
and improved cell membrane permeability.'^^CDs also enhanced the physical stability of 
viral vector formulations for gene therapy.'^' 
Dermal and Transdermal Delivery 
CDs can also be used to optimize local and systemic dermal drug delivery. Applications 
of CDs in transdermal drug delivery include enhancement of drug release and/or 
permeation, drug stabilization in formulation or at absorptive site, alleviation of drug 
induced local irritation, sustaining of drug release from vehicle and alteration of drug 
bioconversion in the viable skin. Parent CDs (a-, P- and y-CDs) and various chemically 
modified CD derivatives, with extended physicochemical properties and inclusion 
capacity have been used in transdermal drug delivery.^ 
Drug thermodynamic activity in vehicles as well as its skin/ vehicle partition coefficients 
can significantly affect CD induced changes in the drug permeability through skin. CDs, 
by enhancing apparent drug solubility, enhance the drug thermodynamic activity in 
vehicles and thus cause enhancement of drug release from vehicles. The enhancement of 
drug release from vehicles by CDs in turn enhances the dermal drug absorption by 
improving the drug availability at the lipophilic absorptive barrier surface (i.e skin).^'^ 
Though drug partition coefficient may be decreased on complexation with CDs, the 
increased drug solubility and thermodynamic activity in vehicles can lead to increased 
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drug permeability througii skin, e.g. increased skin permeability of dexamethasone by 
HP-P-CD.''*° The vehicle type used, due to its main influence on drug's membrane/ 
vehicle partition coefficient, can markedly affect CD induced enhancement of drug 
release. Diffusion rate of ketoprofen from its P-CD and HP-P-CD inclusion complexes 
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was in the order of carbopol gel > o/w emulsion > fatty ointment. Hydrophilic CDs 
improve the release rate of lipophilic drugs from hydrophilic aqueous vehicles. 
Hydrophilic CDs markedly increased the in vitro release rate of corticosteroids from 
aqueous bases (hydrophilic, absorptive, or polyacrylic) but retarded the same from non 
aqueous bases (fatty alcohol, propylene glycol or macrogol). Complexation with P-, DM-
p- and HP-p-CDs increased the release of 4-biphenylacetic acid from hydrophilic 
ointment. P- and HP-P-CDs significantly enhanced the anti-inflammatory effects of 
indomethacin in hydroxyethyl cellulose hydrogels in healthy volunteers.^ It was reported 
that CDs may not affect or even hamper drug release from non-aqueous vehicles and the 
effect may be due to lowered drug solubility in vehicle on complexation. The release of 
prednisolone from non-water containing ointment bases was abated on complexation with 
DM-P-CD. Hydrophilic (3- and HP-P-CDs enhanced the release of hydrocortisone from 
o/w cream and hydrogel but retarded the same from petrolatum vehicle or w/o cream.'''^ 
CDs enhance drug delivery by increasing the drug availability at barrier surface, where 
the free drug partitions from CD cavity into lipophilic barrier. The free drug fraction at 
barrier surface depends on drug dissolution rate, relative magnitude of the stability 
constants of the CD complexes with the drug and the competing agent at absorption site, 
and drug absorption rate constant. In ointments, just as in suppositories, a drug in CD 
complex may be displaced by ointment components, depending on the magnitude of the 
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stability constant of drug/CD complex. Hence, for optimum drug release, the vehicle or 
the CD complex chosen should be such that the complex barely dissociates but still 
maintains a high drug thermodynamic activity in the vehicle.''' The order of prednisolone 
release rate from a hydrophilic ointment was drug alone < y-CD complex < P-CD 
complex < DM-P-CD complex, which was reflective of the order of the complex stability 
constants.^ For absorption, the CD complex has to dissociate to release free drug, the 
actual absorbable species and the dissociation of CD complex depends on the magnitude 
of the complex stability constant. If the complex stability constant is too high the 
complex may not release the free drug at the absorptive site and thus may decrease or 
inhibit drug absorption.'^ The effect of HP-P-CD concentration on the iontophoretic 
delivery of hydrocortisone (i.e higher drug amount delivered at lower CD concentration 
(1%) compared to higher CD concentrations (3 or 5%)) indicated the delivery of only the 
free drug with the CD acting as a carrier.''*^ 
CDs have also been used to reduce drug degradation in topical preparations. P-CD 
maintained the stability of tixoxortol 17-butyrate 21-propionate in vaseline and o/w 
emulsion bases even after 30 days.^ Complexation with CDs was suggested to be a 
rational way to improve physicochemical properties of drugs for transdermal delivery, p-, 
and HP-p-CDs increased the skin permeability of dexamethasone and also improved its 
stability in skin by protecting it against skin metabolism.''"^ CDs, by increasing solubility, 
facilitate drug incorporation into formulation and thus increase the drug concentration in 
the formulation. HP-P-CD increased the amount of piroxicam transported through skin 
but pretreatment of skin with the CD showed no effect on drug retention in skin. Hence 
the CD effect on the drug skin permeability was reported to be due to increased drug 
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concentration in gel and not due to enhancement of drug iontophoretic flux.''*'' 
CDs may alleviate drug induced skin irritation by lowering the extent of free drug 
resulting from inclusion equilibrium. P- and DM-P-CDs significantly reduced 
chlorpromazine induced skin irritation and their alleviating efficacy, DM-P-CD> P -CD 
was consistent with the magnitude of their complex stability constants. Suppression of 
drug penetration into skin caused by the reduction of drug/skin partition coefficient on 
CD complexation was reported to be the possible reason for the reduction of 
chlorpromazine induced skin irritation. P-CD also attenuated the skin irritation induced 
by tretinoin and menadione.^ 
Hydrophobic CDs can modulate drug release from vehicles. Nitroglycerin complexation 
with DE-P-CD accelerated the drug release rate from ointments but the same with P-CD 
retarded the drug release. Hence a combination of the drug complexes with DE-P-CD and 
P-CD was suggested to obtain sustained release percutaneous preparations of the drug.^  
Though only insignificant amounts of CDs and drug/CD complexes can penetrate into 
biological barriers due to their size and hydrophilicity, CDs may interact with some of the 
skin components. It was reported that the free CDs released on complex dissociation, due 
to their ability to remove some membrane surface components, can modify the membrane 
transport properties and thus can facilitate absorption of drugs, especially water-soluble 
drugs. Interaction of RM-P-CD with skin components was directly implicated to its effect 
on drug diffusion. It is also important to pay a careful attention toward possible irritation 
effects of CDs on skin, e.g. RM-P-CD extracted all major classes of lipids from an 
isolated stratum corneum of hairless rats and thereby reduced the barrier function of 
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skin.'^ 
CDs, the safer solubilizing agents with bioadaptability and multifunctional characteristics 
have been evaluated for formulation of poorly water-soluble cosmetic materials. HP-CDs 
increased the aqueous solubility of cosmetic materials, retarded the release rate of 
fragrance materials with no toxicity in topical liquid preparations ^'''^ and also reduced 
permeation rate of eugenol and methyl paraben through hairless mouse skin. Other CD 
applications in cosmetics include masking of smell and stench, stabilization of cosmetic 
materials, e.g. loyal jelly and antiplasmin drugs, assisting in preparation of stable 
emulsion and suspension, inhibition of foaming caused by amphiphilic materials, 
powderization of oily materials, etc. Being non-toxic polysaccharides with solubilizing 
and stabilizing effects as further advantages, CDs and their complexes have been used to 
formulate cosmetic products, making possible those effects that were not realizable with 
common techniques. The ability of CDs to increase stability (against light and oxygen) 
and solubility of sparingly water-soluble molecules made them useful in the formulation 
of cosmetic products.'**^ 
Brain Drug Delivery or Brain Targetting 
The concept of Bodor's chemical delivery system (CDS) (i.e covalent coupling of drugs 
to 1-methyl-l, 4-dihydronicotinic acid through an enzymatically labile linkage, which 
increases drug lipophiiicity) was applied for targeting drugs such as steroids, anti-tumor 
agents and calcium channel antagonists to brain. HoweVer, presence of the lipophilic 
moiety makes prodrugs of CDS poorly water-soluble. HP-p-CD, due to its ability to 
solubilize drugs and also to enhance the chemical stability of dihydronicotinic acid in 
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aqueous solution solved the solubility problems of CDS.'°^ Formulation is an important 
and integral concern in the development of CDS, especially those for brain targeting. 
Formulation development of CDS is based on the need for appropriate dosage form, 
stability, solubility and dissolution characteristics. Loftsson and Brewster discussed the 
use of chemically modified, especially water-soluble CD derivatives such as HP-P-CD in 
the formulation development of CDS. HP-P-CD contributed to the development and 
preclinical testing of a number of CDS by providing a stable and water soluble dosage 
form suitable for parenteral administration.'''^ Use of CDs in the formulation of CDS can 
be demonstrated by the significantly improved solubility, stability and pharmacological 
activity of CDS of thyrotropin releasing hormone analogs on complexation with HP-P-
CD.''*^ It was reported that P-gp mediated peptide transport may play an important role in 
greatly reducing the peptide delivery to central nervous system in v/vo.'^^'^* It was also 
indicated that CDs such as DM-P-CD, due to their inhibitory effect on P-gp efflux 
function, may enhance drug delivery to brain.'•'^  
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Table!: Abbreviations of CDs Discussed in tlie Text 
Cyclodextiiii (CD) 
a- c>xlo dextrin 
p- cyclodextiiii 
y- cyclodextiiii 
Hydiox3^ethyl-(VCD 
Hycliox>?i)ropyl-|3-CD 
Sulfobutylethei-p-CD 
Methyl- |3-CD 
Dimethyl-p-CD 
Randomly dimethylated -^-CD 
Randomly methjdated-P-CD 
Carboxyniethyl - P -CD 
Carboxymethyl ethyl- p-CD 
Dietlwl-p-CD 
Tii-O-metliyl-p- CD 
Tri-O-ethyl-p-CD 
Tii-0-but>ayl-p-CD 
Tri-O-valeiyl-p-CD 
Di-O-hexaiioyl-p-CD 
Glucos>1-p-CD 
Maltos>i-p-CD 
2 -liydioxy-3 -trinietliyl-
ammoiiioiiiopyl- p- CD 
Abbrevation 
a-CD 
p- CD 
7- CD 
HE -p-CD 
HP-p-CD 
SBE-p-CD 
M-p-CD 
DM-p^CD (DIIMEB) 
RDM-p-CD 
RM-p?CD(RAMEB) 
CM-p-CD 
CME-p-CD 
DE-p-CD 
TRIMEB 
TE-p-CD 
TB-p-CD 
TV-p-CD 
DH-p-CD 
G -p-CD 
1 ' 
G -p-CD 
2 ' 
HTIvL4PCD 
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Table-2: Some characteristics of a-, P -, Y -, and 5 -CD 
Type of 
CD 
a-CD 
P-CD 
7-CD 
6-CD 
Cm>ity Diametet' 
A 
4.7-5.3 
6.0-6.5 
7.5-8.3 
10.3-11.2 
MoleaUar 
weigfa 
972 
1135 
1297 
1459 
SolubilUy (g/100 
ml) 
14.5 
1.85 
23.2 
8.19 
Table 3: Factors affecting inclusion complexation 
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Factor 
Type of 
CD 
Ca\ity 
Size ' 
Drug 
Albendazole, 
Mebendazole 
Ricpbcndazole 
Fenoprofen 
Ketq)rofen 
Cocaine 
Gliclazide 
Digit oxin 
Maciocyclic 
conipomids (MCCs) 
Ibuproxani 
ProclJoro-metliazine 
CDs 
studied 
(J-,HP.|5., 
M-P-CDs 
a-, p -, 7 -, 
HP- p-CDs 
M-p-,|i-
CDs 
a-, p -, 7 -
CDs 
p-, a- CDs 
0- CD 
a-,p-,7-. 
6-CDs 
tt-,p-,7-
CDs 
P-,HP.p., 
DM-p-
CDs 
Observation 
Moic effective enliancenient of 
solubilit}^witli substituted CDs. 
Better stability- constant values of 
phannaceutical interest widi only P-
CD and HP- p-CD complexes. 
Better dissolution perfomiance ofM-
P-CD complex. 
Dnig binding witlueasonable affinity 
only to P-CD in aqueous solution. 
Ca\itysize of P-CD was suitable for 
complexation wliile that of a- CD 
insufficient to include GL rings. 
Enlianced solubility due to partial 
inclusion of the drag in CD ca\ity. 
Complexes of smaller MCCs with a-
and P-CDs and those oflargei- MCCs 
with 7" and 6-CDs were relatively 
stable. 
Effective enliancenient of dissolufion 
rate with only witli P- and 7- CDs but 
tliecavit\^  of a-CD was less suitable. 
Decreased solubilit)? due to failme of 
the CD cavities to include 
phenotliiazine ring. 
Ref. 
16 
17 
18 
24 
19 
20 
21 
22 
23 
Table 3: contiiuied 
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Factor Drug CDs studied Observation Ref. 
pH aud 
ioiiisation 
state 
DY-9760e SBE-P-CD 
Sh'ong dnig/ CDiiiteiaction in acidic 
region, at pH 4. 
29 
NSC-639829 SBE-P-CD 
Licreascd solubility' of the catiomc dmg 
atpHl. 
149 
H-615 ET 
H-615 ET 
HP- p -, m.i-
P-, CM-P-, 
SBE-p-
HTMAP-p-
CDs 
Increased solubility with uncharged 
RM-P'CD. Complex stability' constants 
were low with tlic liiglily polar dmg at 
pH 5 due to its lesser ability to enter 
the CD ca\ity but were lugh with 
anionic less polar fomi atpH 10. 
150 
Piroxicam 
Lcvemopaniil 
HCl 
Ziprasdone 
mesylate 
Sulindac 
Mebendazole 
p-CD Effective complexation at low pH 151 
HP-p-CD 
Euliancement of solubility (nig/nil) was 
3 fold with the charged diiig by (7.88 
to 25.(52 at pH 4) and 525 fold with the 
neutral fomi (0.0026 tol.37 atpH 10.6) 
152 
SBE-P-CD 
p-CD 
HP-p-CD 
Complexation was moie favored with 
the ion pail' over the dissociated ionic 
fomi. 
153 
Complexation was easier with non 
ionized fomi 
25 
Unionized form was less included tlian 
the ionized form. 
Table 3: contiimecl 
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Factor 
Tempera tiue 
Drug 
DY-9760e 
SiJindac 
Phenolphtlialein 
Danazol 
CDs 
studied 
SBE-p-
CD 
p-CD 
p-CD 
SBE-(5-
CD 
Observation 
Temperature cliaiige showed negligible 
effect on the stabiht)' constant. 
Licreasuig the temperatiue decreased the 
apparent stability constant. 
hicreasing tlie temperatiue decreased 
decreased association constant for 
binding. 
Licreasing the temperahue decreased the 
complex stability'constant. 
Ref. 
29 
25 
27 
28 
40 
Table 4: Effect preparation method 
Ding 
Albendazole. 
Mebendazole and 
Ribendazole 
Ketopiofen 
Ibiiproxani 
Niniesiilide 
Metliox>-butiopate 
Vitamin D 
2 
Oxazepam 
Sulfamethoxazole 
Glibenclamide 
Tcnoxicani 
CD 
HP-|5-, 
M-p-
CDs 
DM-p-
CDs 
a-, P-, 7 
-CDs 
p-CD 
P-CD, 
HP-p-
CD 
p-CD 
DM-p-
CD 
Pv 
HPH5-
CDs 
p-CD 
(5-CD 
Effect 
Effective inclusion complexation only with 
fi eeze-di^ing but not with co precipitation 
Better dissolution witli Co lyopliilized and 
sealed heated products than kneaded ones 
With p- audy-CDs, spray diying and sealed 
heating resulted in true complexation but 
kneading was ineffective 
Drug dissolution was higher with kneading 
tlian coevaporation 
Solid dispersion gave most effective 
complexation but kneading was 
ineffective.With spray dying complete 
complexation occimed only when the diug/CD 
molar ratio was 1:4. 
Kneading gave good yield but spray drying 
gave complete complexation and best 
dissolution. 
Dissolution behavior was better with spray-
diied s}'stems than the laieaded ones. 
Increased dissolution rate with solid complexes 
prepared by fieeze drying. 
Superior dissolution with ground mixture, 
])hysical mixtiuc and laieaded product 
Neuhalization method showed better dissolution 
pcrfonuance and complex stability than conunon 
solvent and laieading methods. 
Rrf. 
16 
18 
22 
154 
155 
156 
15" 
158 
159 
160 
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Table 5: Effect of various additives 
Effect 
IiiCT eased 
soluWliziug 
effect of ci)s 
(with watei-
soluble 
polymers and 
ioupairing 
aseiits) 
Incieased 
intrinsic 
solubility 
Decreased 
intrinsic 
solubility 
Inliibitoiy effect 
on diTig/ CD 
association 
Dnig 
ETH-615 
Acetazolamide, 
Prazepani and 
Sulfa methoxa zole 
Meloxicam 
Tropicaniide 
Naproxen 
Naphthoquinone 
Clotiimazole 
Clohimazole 
Phenolphthalein 
CD 
CM-p-CD, SBE-
P-CD,HP-|3-CD, 
RM- p -CD and 
HTMAPCD 
HP-p-CD 
P-CD 
HP-p-CD 
P-, M-P-, HP-p-
CDs 
HP-p-CD 
P-CD 
p-CD 
p-CD 
Additive 
Cationic polymer 
hexadimetliiine 
bromide (0.25¥o) 
HPMC. PVP, CMC 
PVP (0.1 to 0.25%) 
HPMC (0.1%) 
Sodium CMC, 
HPMC, PVP K30, 
PEG 6000 
PVPK30 
Water structure 
disruptors. Urea and 
nicotinamide 
Water structiue 
forming agents, 
sorbitol and fiiictose 
Tetrahydrofiiran 
Ref. 
150 
161 
162 
163 
164 
165 
166 
166 
27 
HPMC - Hyd»ox}'lpropyl methyl cellulose 
P \ T - Pol^^inyl pyrollidone 
CMC - Carboxymetliyl cellulose 
PEG - Polyoxyethyl eneglycol 
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Table 6: Summary of regulatory status of parent CDs 
Food Approval 
Product 
a-CD 
pCD 
7-CD 
US 
In 
preparation 
GRAS 
GRAS 
Europe 
Planned 
Food 
Additive 
Pending 
Japan 
Yes 
Yes 
Yes 
Pharmacopeia Monograp 
USP/NF 
No 
Yes 
No 
Ph.Eur 
Yes 
Yes 
In 
Process 
JP 
Yes 
Yes 
No 
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Tabale 7: Examples of CD enhanced solubility and 
dissolution 
CD 
P-CD 
a-CD 
7-CD 
HP-p-CD 
DM-P-CD 
SBE-p-CD 
RM-P-CD 
Randomly 
acetylated 
anioiphoiis-P-
CD (AC-P-CD) 
Drug(s) 
Nimesiilide, Sulfomethiazole, 
Lorazepam, Ketoprofen, 
Griseofiilvin, Praziquante 1, 
Qilorthalidone, Etodolac, 
Piroxicam,, Itiaconazole, 
Ibupiofen 
Praziquantel 
Praziquantel, Omeprazole, 
Di^oxin 
Albendazole, DY- 9760e, 
ETH-615, Levemopamil HCl, 
Sulfomethiazole, Ketoprofen,, 
Griseofiilvin, Itraconazole, 
Carbamazepine Zolpidem, 
Phenytoin, Rutin 
Naproxen, Camptothesin 
DY- 9760e, Danazol, 
Fluasterone, Spiranolactone 
ETH-615, Tacrolimus 
Naproxen 
Ref. 
36,154,158,17 
0-178 
36 
36,48,179 
16,29,34,50,5 
1,52,150,152, 
158,171,173,1 
77 
35,66 
28,29,180,181 
74.150 
182 
Table 8. CD effect on drug stability 
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Effect 
tPhotostability 
t shelf life with 
unaffected 
dissolution rates for 
4 years 
t thermal stability in 
solid state 
tStability against 
intramolecular 
cyclization in solid 
state 
tStability to acid 
hydrolysis and 
photodecomposition 
tStability against 
hydrolysis 
t Deacetylation or 
degradation 
tPhotoreactivity 
Drug 
Promethazine 
DY-9760e 
2-ethyl hexyl p-
dimethyl 
aminobenzoate 
Glibenclamide 
Diclofenac sodium 
Quinarii 
Doxorubicin 
acyl ester 
prodrugs of 
Ganciclovir 
Digoxin 
Rutin 
Camptothesin 
Melphalan & 
Carmustine 
Paclitaxei 
Spiranolactone 
Flutamide 
CD 
HP-p-CD, DM-p-CD 
SBE-p-CD 
HP-p-CD 
p-CD 
p-CD 
p-CD, HP-p-CD 
HP-p-CD, HP-Y-CD 
HP-p-CD 
y-CD 
HP-p-CD 
RDM-p-CD 
SBE -p-CD, HP-p -
CD 
Y-CD, HP-Y-CD, HP-p 
-CD 
SBE-a-CD, SBE-p-
CD, HP-p-CD, Y-
CD,p-CD 
p-CD 
Ref. 
150 
29 
56 
62 
63 
64 
183 
171 
48 
52 
66 
68 
184 
69 
70 
Table 9: Applications of CDs in oral delivery 
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Effect 
t bioavailability by 
tsolubility and 
dissolution rate 
t intensity or duration 
of therapeutic activity 
t permeability 
tgastrointestinal 
stability 
tSublinguai 
bioavailability 
tbuccal bioavailability 
Drug 
p-CD 
HP-P-CD 
SBE7-(3-
CD 
DM-p-CD 
M-p-CD 
ME-p-CD 
P-CD 
HP- p-CD 
HP-p-CD 
y-CD 
HP-p-CD 
HP-p-CD 
SBE7-P-
CD, HP-p-
CD 
CD 
Ketoprofen, 
Griseofulvin, 
Terfenadine 
Albendazole, 
Ketoprofen, Phenytoin, 
Gliclazide 
Spiranolactone 
Tacrolimus 
Albendazole 
Phenytoin 
Terfenadine, 
Tolbutamide 
Tolbutamide, 
Amylobarbitone 
Flutamide 
Digoxin 
Rutin 
Clomipramine, 
Testosterone 
Danazole 
Ref. 
75,171,172 
16,51,171,185 
181 
74 
16 
51 
75,76 
76,78 
72 
48 
52 
73,79,80 
129-
130(81,82) 
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Table 10: Some of the examples of usage of CDs iii aqueous eyes drop solution 
Drag 
Acetazolainide 
Aiacliidoiij'lethauolamide 
C\'closi)oiiiie 
Dexametliasone 
Dexametliasone acetate 
Diclofenac 
Pilocarpine 
Pilocarpine produgs 
CD 
HP-p-CD, a.-CD,HP-p-CD 
HP-p-CD 
a-CD 
HP-I5-CD 
HP-I3-C3) 
HP-|i-CD,M-|5-CD 
HP-|3-CD,a-CD,|5-CD, 
HP-p-CD,SBE-p-CD 
HP-P-CD 
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Table 11: Modification of the drug release site and/or time profile by CDs 
Release pattern 
Iimiediate 
realease 
Prolonged 
release 
Modfied release 
Delayed, pH 
dependent 
release 
Site-specific 
rdease 
Aim 
Enhanced dissolution and absoq)tion 
of poorly water-soluble dugs 
Sustained release of water- soluble 
drugs 
More balanced oral bioavailabilit}' 
with prolonged theiapeutic effects 
(Enteric) Acid protection of drags 
Colon-targeting 
Use of CD 
HP-p-,DM-p-,SB-p-and 
branched-p-CDs 
Etliylatedp-CDs,Ac)'lated 
P-CDs 
Simultaneous use of 
different CDs and/or otii«' 
excipients 
CME-p-CD 
Drug-CD conjugate 
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Table 12: Applications of various CD derivatives in the formulation 
of modified release preparations 
Derivative 
Dietlwl-p-CD 
Triacet>i- p -CD 
Peraqlated- p -CD (TB- p 
-CD) 
Al- p -CD-sulphate 
0-caiboxyineth\l-
0- P -CD 
Drag 
Diltiazem 
Buserelin acetate 
Nitroglycerine 
Isosorbide dinitrate 
Tiaijrofenic acid 
Flufenaiiiic acid 
Molsidomine 
Salbutaniol 
Captopril 
Recombinant 
human basic 
fibroblast growth 
fee tor 
Molsidomine 
Diltiazem HCl 
Suimnaiy 
Sustained release for oral use 
Sustained release for subcutaneous 
use 
Sustained release for peraitaneous 
use 
Sustained release 
Delayed release 
Prolonged release for oral use 
Sustained release for oral use 
Prolonged release for oral use 
Sustained release 
Sustained release for oral use; 
enhanced stability' 
Delayed release 
DISCUSSION 
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Structure determination is of particular importance for supramolecular host-guest 
complexes, which are the basis of most CD applications in medicine, catalysis, separation 
and sensor technology and also food chemistry. Pharmaceutical uses of CDs for drug 
protection or targeting now legally require structure determination of the administered 
compounds. 
NMR spectroscopy is one of the most important tools for the structural elucidation of 
organic compounds, particularly in the solution state. The method is of increasing 
significance for most CD application studies. There are few alternatives to NMR 
spectroscopy in the CD related studies.'*^''** As with many carbohydrates, it is often 
difficult to obtain single crystals of CD derivatives and then to analyse them by X-ray 
crystallography, or by neutron diffraction. Other techniques such as fluorescence, UV/vis 
spectroscopy, calorimetry etc are useful in the study of complexation energetics with CDs 
but provide indirect and qualitative information about inclusion modes and geometries. 
The most obvious incentive to use NMR techniques for the investigation of CD 
complexes is the interest to understand the driving forces and binding modes in these 
non-covalent associations, and then to make optimal use of these factors for new 
applications. It should be remembered that the driving force for CD inclusion often is of 
solvophobic nature and that most CD applications involve action in a liquid matrix, 
which again emphasises the role of NMR spectroscopy as the most important method 
applicable in solution. 
Demarco and Thakkar,'^^ first reported the use of NMR spectroscopy to study inclusion 
phenomenon and there has been a virtual explosion of such studies since then. The older 
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work was restricted to the observation of few CD protons, mostly at the anomeric centers 
which were sufficiently separated from strongly coupled other signals. The advent of 
high-field instruments and in particular 2D methods has completely changed the 
situation, and the possibilities of now available NMR techniques are far from being 
exploited. 
Also, these tasks represent a fascinating challenge for the NMR spectroscopist in view of 
the high complexity of the underlying cycloamylose ' H NMR spin systems. These are 
characterised by signals which, apart from the anomeric proton, absorb in a range of only 
0.5 ppm and are strongly coupled. In addition, the shielding effects of the CD cavity on 
the included guest molecules are limited to a few tenths of a ppm at most. 
Demarco and Thakkar'*^ noticed the highfield chemical shift changes in the P-CD cavity 
protons, namely H-3' and H-5', in the presence of a variety of aromatic substrates in 
aqueous solution and envisaged from these observations that the aromatic ring is 
positioned in the P-CD cavity. He used 100 MHz instrument for these studies which is 
actually not suited for this type of work because all the CD protons, except H-l', resonate 
in the 0.5 ppm range and are not easily distinguished. He established the assignment for 
each proton on the basis of analysis of individual splitting patterns and coupling constants 
at 220 MHz, decoupling experiments and expected chemical behavior i.e. H-3' and H-5', 
being 1, 3-diaxiaI to the Ci axial oxygen should resonate at lower fields than the H-2' and 
H-4' protons. 
At magnetic fields above 9.4 T, corresponding to 400 MHz for the ' H NMR spectra, the 
dispersion is high enough to locate, in conventional ID NMR spectrum, most of the CD 
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protons, eased by the high symmetry of the macrocycles. ' H N M R spectrum of P-CD in 
aqueous solution has already been studied in detail. It has been established that, on the 
NMR time scale, all the seven glucose units have identical conformations and the 
molecule is highly symmetrical. Furthermore, the magnitude of the vicinal coupling 
constants Ji_ 2 through to J4^ 5 are consistent with the Ci chair form for the glucose units of 
CDs.''^ 
It is now well accepted that the signals of the cavity protons move highfield when the 
guest molecule or a part of it enters the CD cavity. The chemical shift change data 
obtained from ' H NMR titration experiments can be used to obtain detailed information 
about the structure of the complex. The magnitude of the chemical shift changes for the 
protons positioned in the CD-cavity, A5H-3' and A5H-5', increases with an increase in the 
concentration of the guest'^' while that for guest protons increases with an increase in the 
concentration of the CD.'^^ The magnitude of the A5H-3' and A5H-5' also depends on the 
nature of the guest. The chemical shift changes are high in the case of aromatic guests 
while these are relatively small if the aliphatic guest enters the CD cavity.'^^ 
The CDs generally act as one site ligand and the guest enters the cavity from wider rim 
side. This is always true for a-CD but in the case of p- and y-CD, complexes formed by 
the penetration of the guest from the narrower rim side have also been reported. The 
relative chemical shift change data for the cavity protons (A6H-3' and A5H-5') is sometimes 
taken as an evidence for the mode of penetration of the guest. It has been suggested that 
in the cases where A5H-3'>A6H-5' the guest entry is from wider side'^ ** and vice versa.'^ ^ 
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This statement may, however, be true only when the guest is bulky but can not be 
generalized. 194 
Rekharsky,'^^ however, made a detailed NMR study of the CD inclusion complexes of a 
variety of guests and showed that while the magnitude of the chemical shift changes for 
H-3' and H-5' protons is a quantitative measure of the stability of the complexes, their 
ratio, A8H-5'/A6H-3') is related to the depth of penetrations of the guest into the CD cavity. 
In all the studied case, the guest approached the P-CD cavity from wider rim side though 
A5H-5'>A6H-3'. He showed that higher magnitude of A5H-3' and ASH-S- values is due to 
higher stability of the complex. On the other hand, their ratios, A5H-5'/A5H-3', which were 
found as high as 1.2-3.0 for P-CD, indicate a deep penetration of the guest into the host 
cavity. It becomes obvious from these examples that the use of relative magnitude of 
chemical shift data for cavity protons as an evidence in support of the mode of 
penetration of guest into the cavity cannot be generalized. In fact the mode of penetration 
can be best established from the NOE experiments. 
The formation of the CD inclusion complex also results in the concomitant chemical shift 
changes for the guest protons and generally all the guest protons, and not only the part 
included in the CD cavity, show downfield shift changes, but sometimes upfield changes 
have also been observed. These changes have mostly been found to be of qualitative 
significance though these may also provide important information regarding the structure 
of the complex. 
It is not possible, sometimes due to poor water solubility of the guest, to use high 
concentration of the guest in the NMR titrations and in such cases the chemical shift 
53 
changes observed for the CD cavity protons may be very insignificant while large 
chemical shift changes are observed for guest protons. The chemical shift change data for 
guest protons can also be used for determining stoichiometry and binding constant of the 
complex but whether guest enter the CD cavity or not can only be said on basis of 
chemical shift changes in the cavity protons. 
Stoichiometry and Binding Constant of the Complex 
The most commonly claimed stoichiometric ratio for CD complexes is 1:1 which is 
usually justified. Nevertheless, other ratios are known, most common of these probably 
being 2:1 (H/G). The ratios 1:2 (H/G) and 2:2 have also been reported. Before any 
structural or association constant determination is performed, it is always essential to 
determine the stoichiometry of the host-guest complex which is readily achieved from 
NMR titration data. There are several methods used to determine the stoichiometry, 
namely continuous variation (Job's Plot)'^\ molar ratio'^* and several modified Benesi-
Hildebrand methods. 
Modifications of Benesi-Hildebrand Method 
Assuming the composition of the complex to be 1:1, the following expression can be 
written: 
G + H ^ GH 
The association constant of the complex (Ks) is given by 
[GH] 
Ka= [H] [G] 
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where [H], [G] and [GH] are equilibrium concentrations of host, guest and complex, 
respectively. Benesi-Hildebrand studied the complexation of iodine with aromatic 
hydrocarbons by UV-visible spectroscopy'^^ and derived the following linear equation 
(1) for the calculation ofKa. 
l/8obs = l / ( ^ £max[H]) + 1/s max (1) 
where Eobs is the extinction of a layer of solution 1 cm deep containing m moles of h and 
8max is the molar extinction coefficient of the complex at the wavelength of maximum 
absorption. NMR version of the Benesi-Hildebrand equation (2) was independently 
derived by Mathur et aP*^ and Hannah and Ashbaugh.^°' 
1/A8„bs = l/(^aA8max[H]) + 1/A6n,ax (2) 
where A6obs = (So-Sobs) and ASmax =(5G-6GH)- A plot of l/A5obs against 1/[H] (often 
referred to as a double reciprocal plot) should be linear for a 1:1 complex, with a slope 
l/A]'aA5max and intercept 1/A6max allowing the determination of association constant (Ka). 
This expression is valid when observing one species in presence of a large excess of the 
other species. 
An alternative solution of Benesi-Hildebrand equation has been proposed by Foster and 
Fyfe (3). This is a special form of the more general Scatchard plot. 
A5obs/[H] = - / : aA8obs+^aA5n ,ax (3) 
In the Foster-Fyfe procedure, a plot of A5obs/[H] against A5obs (referred to as an x-
reciprocal plot) should be linear for a 1:1 complex. The gradient is equal to -K^ and the 
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intercept gives A5max- This modification requires an extrapolation to infinite dilution and 
the Ka is not dependent on the extrapolation. 
Another modification of Benesi-Hildebrand equation is Scott equation (4)?°'* 
[H]/A5obs = [H]/A5^ax + A5,ax//^a (4) 
In the Scott procedure, [H]/A5obs is plotted against [H] (referred to as an y-reciprocal plot) 
which should be linear for a 1:1 complex with a slope 1/A5max and intercept A5max/Ka 
allowing the estimation of association constant {K^). 
b^-^t >A'jV'b^ ' \ ) J • / 
"n Um^' 
Throughout the above discussion it is assumed that the guest molecule is the observed 
species. It does not matter which species is observed and the most readily observed and 
responsive molecule would normally be chosen. The data treatment for observed host is 
identical, with host and guest symbols switched. 
Throughout discussion the CD protons are numbered as H-1' to H-6'. 
NMR SPECTROSCOPIC STUDY 
OF COMPLEXATION OF 
AMLODIPINE BESYLATE WITH 
P-CYCLODEXTRIN 
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Amlodipine besylate, FW 409, chemically described as 3-ethyl-5-methyl (±)-2-[(2-
aminoethoxy)methyl]-4-(2-chlorophenyl)-l,4-dihydro-6-methy 1-3,5-
pyridinedicarboxylate, monobenzenesulphonate, commonly known as Norvasc, is a 
long-acting calcium channel blocker, having empirical formula 
C20H25ClN2O5*C6H6O3S 205-207 
,-^^^X 
M-i^ 
H2l\r 
0 H 
AinlodiDiiie 
SOqH 
2" 
3" 
4" 
Benzeiiesiilpliomc Acid 
Amlodipine besylate is a white crystalline powder, slightly soluble in water and 
sparingly soluble in ethanol. It is formulated as white tablets equivalent to 2.5, 5 and 
10 mg of amlodipine for oral administration. In addition to the active ingredient, 
amlodipine besylate, each tablet contains microcrystalline cellulose, dibasic calcium 
phosphate anhydrous, sodium starch glycolate, and magnesium stearate. 
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-
channel blocker) that inhibits the transmembrane influx of calcium ions into vascular 
smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds 
to both dihydropyridine and nondihydropyridine binding sites. The contractile 
57 
processes of cardiac muscle and vascular smooth muscle are dependent upon the 
movement of extracellular calcium ions into these cells through specific ion channels. 
Amlodipine inhibits calcium ion influx across cell membranes selectively, with a 
greater effect on vascular smooth muscle cells than on cardiac muscle cells. 
Amlodipine is a peripheral arterial vasodilator.^"^ that acts directly on vascular smooth 
muscle to cause a reduction in peripheral vascular resistance and reduction in blood 
pressure. The precise mechanisms by which amlodipine relieves angina is not fully 
understood but are thought to include the following: 
Exertional Angina: In patients with exertional angina, amlodipine reduces the total 
peripheral resistance (afterload) against which the heart works and reduces the rate 
pressure product, and thus myocardial oxygen demand, at any given level of 
209 
exercise. 
Vasospastic Angina: Amlodipine has been demonstrated to block constriction and 
restore blood flow in coronary arteries and arterioles in response to calcium, 
potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal 
models and in human coronary vessels in vitro. This inhibition of coronary spasm is 
responsible for the effectiveness of amlodipine in vasospastic angina.^''* 
We have studied the complexation of amlodipine besylate with P-cyclodextrin in 
aqueous medium at room temperature by one and two dimensional ' H N M R 
spectroscopy. Amlodipine besylate was generously donated by INTAS 
Pharmaceuticals Ltd., while P-cyclodextrin was obtained from Cerestar Application 
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Center, Food & Pharmaceutical Specialities, France, and these were used without any 
further purification. All the NMR spectra were recorded, in D2O and at room 
temperature, on a Bruker a-500 MHz instrument. No external reference was used and 
the chemical shift values (5) are reported in ppm, corrected with reference to HDO 
peak at 4.8000. Four samples of mixtures of amlodipine besylate and P-cyclodextrin 
(G/H) were prepared in various ratios ranging from 0.310 to 1.145. The concentration 
of the drug was kept constant at 9 mM while the concentration of P-cyclodextrin was 
varied from 7.8 to 29 mM. The molar ratios of the mixtures were calculated by direct 
integration of the appropriate signals. Distinct peaks were not observed for bound and 
free form of the drug due to the rapid exchange of drug between free and bound state 
on the NMR time scale. Chemical shift changes (5A) were calculated according to the 
formula: 
6A = 8(complex) - 5(free) 
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Fig. 9. 2D COSY spectrum (500 MHz) of a mixture of amlodipine 
besylate and P-CD having (G/H) equal to 0.565 
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^H NMR Chemical Shift Change Data of p-CD 
For any kind of structural study of p-cyclodextrin inclusion complexes by NMR 
spectroscopy, an unambiguous assignment of each and every signal of cyclodextrin as 
well as guest molecule is the basic requirement. The assignment of P-cyclodextrin 
proton signals was made with the help of characteristic position and splitting pattern 
of the signals along with the COSY spectral data, of a mixture of P-cyclodextrin and 
amlodipine besylate. The interactions of all the p-cyclodextrin protons with each other 
are depicted in the part of the COSY showing P-cyclodextrin protons (Fig. 10). The 
signal for H-l' appears around 5.00, away from all the other p-cyclodextrin protons, 
and is easily identified. All the other signals, which appear in a narrow range of 0.5 
ppm, are characterized with the help of H-l' signal. In the presence of amlodipine 
besylate, signals for the cavity protons of P-CD showed significant upfield shift 
changes (Fig. 11). Though other p-CD protons also exhibited shifts in their signals 
but these were relatively insignificant. 
The inclusion of an aromatic guest molecule into the p-CD cavity generally produces 
highfield shift changes in the cavity protons of P-CD due to the anisotropic shielding 
by aromatic ring on the P-CD protons situated above or below the 7i-electon cloud of 
the aromatic ring. Thus, highfield shift changes in the protons situated in the p-CD 
cavity (H-3' & 5') in the presence of amlodipine besylate confirm the formation of 
inclusion complex between amlodipine besylate and P-CD, under the studied 
conditions, as reported earlier.' '^ ' ' ' ' '^ ^ The mode and depth of penetration of the 
guest in the P-CD cavity will be discussed later. 
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Fig. 11. Part of the ' H N M R spectra showing P-CD cavity proton signals 
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' H N M R Spectral Assignment and Chemical Shift Change Data of 
Amiodipine Besylate 
To establish the detailed structure of the amlodipne besylate and |3-cyclodextrin, 
assignment of amiodipine besylate protons in the free as well as complexes form was 
required which was made with the help of COSY spectral data performed on a 
mixture of drug and p-cyclodextrin (Fig. 12). A triplet in the highest field was 
observed at 1.129 which interacted with the multiplet at 4.012. These were attributed 
to ethoxycarbonyl group protons. A singlet at 2.289 was assignable to methyl group at 
C-6 of dihydropyrine. The signal for CH3O- was observed at 3.546 as a singlet. The 
protons for 2-aminoethoxyl group were observed as a doublet of double at 3.182 and a 
multiplet at 3.802 which were confirmed by COSY data. Two multiplets observed at 
3.432 and 3.802, each inetgratting for one from were ascribed to -(C-2)-CH2-0-
protons. The NH2 protons were observed as a pair of doublets at 4.618 and 4.746 
while NH of dihydropyridine was observed as a singlet at 5.377. 
The aromatic region of the spectrum displayed signals for besylate as well as for 2-
chlorophenyl ring and these did not interfere with each other and were, therefore, 
easily identified. A doublet of doublet, for two protons, at 7.782 and a multiplet at 
7.382 for three protons were assigned to besylate with the help of COSY spectral data. 
Four protons of 2-chlorophenyl ring were observed as two doublet of triplets at 7.042 
(H-4) and 7.129 (H-5) and two doublets of doublets at 7.192 (H-6) and 7.342 (H-3), 
respectively. 
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Fig. 12. Part of the COSY spectrum of a mixture of P-CD 
and amiodipine showing aromatic region 
In the presence of P-CD, most of the amiodipine and besylate proton signals displayed 
downfield chemical shift changes but aromatic proton signals displayed very 
significant shift of signals compared to non-aromatic ones (Fig. 13 & Table). The 
signals for 2-aminoethoxymethyl group attached to dihydropyridine ring could not be 
studied because they merged with P-CD protons. For any further structural study of 
the inclusion complex formed between amiodipine and P-CD, stoichiometry of the 
complex must be determined. 
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Fig. 13. ' H N M R spectra of pure amlodipine (A) and mixtures of amlodipine 
besylate and P-CD (B-E) showing aromatic regions 
Table: Chemical shift change (A5) data for Aromatic proton of 
amlodipine besylate 
Proton 
H-4 
H-5 
H-6 
H-3 
H-2", 6" 
H-4" 
H-3", 5" 
[G]/[H]=0.310 
0.193 
0.170 
0.192 
0.143 
0.213 
0.266 
0.075 
[G]/[H]=0.565 
0.188 
0.179 
0.199 
0.156 
0.202 
0.252 
0.059 
[G]/[H]=0.832 
0.184 
0.172 
0.192 
0.148 
0.2 
0.251 
0.055 
[G]/[H]=1.145 
0.176 
0.165 
0.184 
0.142 
0.197 
0.257 
0.052 
Determination of Stoichiometry of the AmIodipine-P-CD complex 
The stoichiometry of the complex was determined by Scott's modification of Benesi-
Hildebrand equation as described earlier. 
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[H]/A5obs = [H]/A5n,ax+ A5„,3x/^a 
(5) 
where [H] is the concentration of P-CD, A§obs ~ (5G-5obs) and A5max = (5G-5GH) -^ a is 
the apparent binding constant of the complex.. A plot of [H]/A5obs against [H] gave an 
excellent linear fit for chlorophenyl ring proton as well as for ring protons of besylate 
suggesting that both the amlodipine as well as besylate have formed 1:1 inclusion 
complexes with P-CD (Fig. 14). 
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OJllO 0.015 0.020 0.025 01)30 
IH] M 
Fig. 14: Scott's plot aromatic protons of amlodipine and besylate 
It is quite obvious that dihydropyridine ring of amlodipine can not penetrate the p-CD 
cavity because of the presence of several bulky groups and so it can be argued that 
complex is formed by the entry of chlorophenyl ring of drug into the cavity of p-CD. 
The mode of penetration is most probably from wider side of the cavity because 
chemical shift changes for H-3' are higher compared to H-5' but there is some degree 
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of uncertainty which could only be removed by ROESY spectral data which could not 
be obtained. The structures of the complexes are given below. 
0 H 
Ho|\r 
SO3H 
Proposed Structures of Two 1:1 inclusion complexes formed 
between amlodipine besylate and P-CD 
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CONCLUSION 
' H N M R spectroscopic study of pure amlodipine besylate, pure p-CD and mixture of 
these two in water at room temperature confirmed the formation of two 1:1 P-CD-
amlodipine besylate inclusion complexes, involving penetration of aromatic ring into 
the P-CD cavity, whose structures have been proposed. Both the amlodipine and 
besylate were found to be involved in the complexation. 
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